Johnson & Johnson

- No new fundraising through debt or equity was mentioned in the provided excerpts. - The company completed the Kenvue separation, generating significant cash and value through the Kenvue debt offering and IPO. - Johnson & Johnson reduced its outstanding share count by approximately 7% (191 million shares) through this separation. - The company retained about 180 million shares of Kenvue stock for future cash proceeds. - No indications of planned new debt or equity financing were noted; focus remains on using strong free cash flow and credit profile for capital allocation. - Capital allocation priorities include investing in the business, increasing dividends annually, strategic business development, and share repurchases.

- Johnson & Johnson is progressively increasing manufacturing capacity for Carvykti, including expansion at the New Jersey launch site, a manufacturing site in Belgium, and utilizing excess Novartis capacity. - A new factory is being built in the Netherlands to support the lentivirus component of Carvykti, expected to be available next year. - A restructuring program in MedTech (Orthopedics) aims to simplify operations, exit certain markets/product lines, and improve margins; this includes inventory write-downs and modest revenue impact over two years, completing by end of 2025. - Multiple clinical development programs for oral peptide J&J-2113 are being initiated, including Anthem (starting this month) and ICONIC phase 3 expected in November. - Continued innovation and clinical trials in electrophysiology and pulse field ablation technologies, including catheter development. - Enterprise business review planned to discuss long-term strategy and pipeline investments.

- MedTech procedural growth expected at 5%-7% in 2024, maintaining elevated market levels seen in 2023. - Launch of new products like the first PFA catheter in Europe anticipated to fuel MedTech growth. - Bariatric surgery business expected to benefit indirectly from increased obesity treatment awareness and complementary use with GLP-1s, despite some short-term patient reconsideration. - Immunology portfolio, especially Tremfya, projecting robust growth with new indications in ulcerative colitis and Crohn’s disease. - Innovative Medicines unit targets $57 billion revenue by 2025, driven by growth in key assets (Tremfya, Erleada, DaVinci) and new product launches such as Carvykti and Tecvayli. - Oncology pipeline shows promise with upcoming pivotal data (e.g., MARIPOSA study) expected to set new standards. - China remains a key growth driver despite it facing some price headwinds from value-based procurement. - Capacity expansions in manufacturing anticipated to support growing demand, especially for therapies like Carvykti.

- **2023 Guidance Raised:** Expect operational sales growth of 8.5% to 9%, with adjusted pre-tax operating margin improving by approximately 50 basis points versus prior year. - **2024 Outlook:** - Flat procedures expected in MedTech, with market growth of 5% to 7%—no margin guidance yet but margins anticipated to be similar to 2023 start. - Earnings per share benefits expected in 2024 from share count reduction post-Kenvue separation. - **Innovative Medicines:** Confident in growth from key brands, with multiple data readouts and regulatory filings upcoming. Anticipate continued strong growth driven by Tremfya, Carvykti, Tecvayli, Talvey, and pipeline advancements. - **Stelara Biosimilars:** Not expected to enter US market in 2024, preserving revenue. - **Long-Term Confidence:** Johnson & Johnson expects to meet $57 billion pharma revenue target by 2025 and is well-positioned for growth into the second half of the decade.

The provided transcript does not contain specific information regarding current or expected orderbook or pending orders for Johnson & Johnson. The discussion primarily covers: - Growth and performance of various portfolios including immunology, MedTech, and pharmaceuticals. - Progress and updates on products like Ottava robotic surgery platform, Carvykti, Tremfya, Stelara, and MARIPOSA clinical trial. - Capacity expansions and manufacturing improvements for cell therapies. - Market outlooks including procedural growth, pricing pressures, and launch strategies. - Litigation updates and strategic approach to talc-related lawsuits. - No explicit mention of orderbook volume, pending orders, or backlog data. For precise orderbook details, additional specific reports or financial disclosures beyond this transcript would be needed.